Cargando…

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists

BACKGROUND: Risk scores for patients who are at high risk for major bleeding complications during treatment with vitamin K antagonists (VKAs) do not perform that well. BLEEDS was initiated to search for new biomarkers that predict bleeding in these patients. OBJECTIVES: To describe the outline and o...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Rein, Nienke, Lijfering, Willem M., Bos, Mettine H. A., Herruer, Martien H., Vermaas, Helga W., van der Meer, Felix J. M., Reitsma, Pieter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147785/ https://www.ncbi.nlm.nih.gov/pubmed/27935941 http://dx.doi.org/10.1371/journal.pone.0164485

Ejemplares similares

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
por: van Heteren, D. Max, et al.
Publicado: (2022)

Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
por: Bakker, Sanne, et al.
Publicado: (2022)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Comparison of bleeding risk scores and evaluation of major bleeding predictive factors in patients with major bleeding due to vitamin K antagonist use
por: Yildirim, Sinan, et al.
Publicado: (2023)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
por: van der Meijden, Paola E. J., et al.
Publicado: (2013)

Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding
por: Schreuder, Mark, et al.
Publicado: (2019)

Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis
por: Skaistis, Joel, et al.
Publicado: (2015)

Efficacy and safety of activated prothrombin complex concentrate for the reversal of vitamin K antagonist major bleeding
por: Sheikh-Taha, Marwan, et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence?
por: Lijfering, Willem M., et al.
Publicado: (2018)

Lipid levels and risk of venous thrombosis: results from the MEGA-study
por: Morelli, Vânia M., et al.
Publicado: (2017)

Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
por: Ben Mbarka, F., et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies
por: Roskell, Neil S., et al.
Publicado: (2013)

Risk of drug-related upper gastrointestinal bleeding in the total population of the Netherlands: a time-trend analysis
por: Bedene, Ajda, et al.
Publicado: (2022)

A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk
por: Reitsma, Pieter H, et al.
Publicado: (2005)

Major bleeding risk with non‐vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta‐analysis
por: Huang, Wen‐Yi, et al.
Publicado: (2020)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
por: Komen, Joris, et al.
Publicado: (2022)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery
por: Manfredini, Mattia, et al.
Publicado: (2021)

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists in 649 fast-track total hip and knee arthroplasties
por: Jørgensen, Christoffer C, et al.
Publicado: (2017)

Warfarin: Major bleeding complication manifesting as retroperitoneal bleed: case report
Publicado: (2020)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists
por: Liabeuf, Sophie, et al.
Publicado: (2016)

Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing
por: Bloemen, Saartje, et al.
Publicado: (2017)

Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies
por: Anghel, Larisa, et al.
Publicado: (2020)

Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry
por: Pfeilschifter, Waltraud, et al.
Publicado: (2022)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
por: Giorgi-Pierfranceschi, Matteo, et al.
Publicado: (2015)

ptFVa (Pseudonaja Textilis Venom-Derived Factor Va) Retains Structural Integrity Following Proteolysis by Activated Protein C
por: Schreuder, Mark, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_me5bo5mtnfuvmk5k7ph8moeoi6